Yuqing Xue, Natalia Antonides-Jensen, Fernando Flores-Guzman, Lydia L. Wu, Jacky Gomez-Villa, Muskan Singh, Kenneth B. Bader, Sonia L. Hernandez, Mark A. Applebaum
{"title":"Abstract A029: Histotripsy induces an anti-tumor immune response with an abscopal effect in a syngeneic neuroblastoma mouse model","authors":"Yuqing Xue, Natalia Antonides-Jensen, Fernando Flores-Guzman, Lydia L. Wu, Jacky Gomez-Villa, Muskan Singh, Kenneth B. Bader, Sonia L. Hernandez, Mark A. Applebaum","doi":"10.1158/1538-7445.pediatric25-a029","DOIUrl":null,"url":null,"abstract":"Background: Despite recent therapeutic advances, patients with high-risk neuroblastoma (NB) remain in need of improved treatment options. Histotripsy is a focused ultrasound therapy for nonthermal-tissue ablation via bubble activation. Recent pre-clinical and clinical reports suggest histotripsy stimulates an anti-tumor immune response in the adult population. We previously demonstrated that histotripsy ablation of NB xenograft tumors enhances tumor necrosis factor-alpha secretion, inducing apoptosis. We hypothesized that histotripsy induces both local and distal abscopal anti-tumor immune response in neuroblastoma, resulting in increased killing of tumor cells. Methods: Myc-expressing neuro-2a cells were subcutaneously and synchronously injected into each flank of immunocompetent A/J mice. Histotripsy was applied with a custom system to approximately 80% of one flank tumor when it reached 200 – 300 mm3. Six days later, single cell RNA sequencing (scRNAseq) libraries were prepared for histotripsy treated tumors, synchronous contralateral tumors, and tumors from untreated control mice. Sequencing files were processed with Cell Ranger and downstream analyses were done with Seurat, followed by Kruskal-Wallis test for cell proportions comparison. Flow cytometry was used to corroborate these findings using anti-CD8 (T cells) and CD11b (macrophages). Results: Tumors from untreated control mice were over two-fold larger than both histotripsy-treated tumors six days after treatment (p=0.03) as well as tumors contralateral to the histotripsy treated tumors (p<0.05), suggesting an abscopal effect. High-quality scRNAseq data were obtained from 3 untreated tumors and 2 each from histotripsy and contralateral tumors. The proportion of cytotoxic CD8+ T cells were significantly higher in histotripsy as well as contralateral tumors compared to untreated controls (p=0.029). Similarly, anti-tumor M1 macrophages had a non-significant trend higher (p=0.27) while pro-tumor M2 macrophages were significantly decreased (p=0.029) in controls compared to treated and contralateral tumors. These findings were validated with flow cytometry of both CD8 and CD11b markers (p<0.05, respectively). NB cells from treated and contralateral tumors had decreased Myc expression (p<0.001) in addition to suppression of cell cycle and growth-related pathways relative to control tumors, including Myc targets, G2M checkpoint, and E2F targets pathways (p<0.001, respectively). Treated and contralateral tumor cells also had activated expression pathways of inflammatory response, regulation of chemokines and cytokines, response to interferon, and antigen processing and presentation when compared to controls (p<0.001, respectively). Conclusions: Our findings show that histotripsy can generate an immune cell activation response in treated and distal tumors in NB models, reducing proliferation of the targeted tumor as well as having an abscopal effect. These findings suggest that histotripsy may sensitize NB tumors to T cell dependent targeted strategies such as PD-1 inhibition. Citation Format: Yuqing Xue, Natalia Antonides-Jensen, Fernando Flores-Guzman, Lydia L. Wu, Jacky Gomez-Villa, Muskan Singh, Kenneth B. Bader, Sonia L. Hernandez, Mark A. Applebaum. Histotripsy induces an anti-tumor immune response with an abscopal effect in a syngeneic neuroblastoma mouse model [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer— From Biology to Breakthrough Therapies; 2025 Sep 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_2): nr A029.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"23 1","pages":""},"PeriodicalIF":16.6000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1538-7445.pediatric25-a029","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Despite recent therapeutic advances, patients with high-risk neuroblastoma (NB) remain in need of improved treatment options. Histotripsy is a focused ultrasound therapy for nonthermal-tissue ablation via bubble activation. Recent pre-clinical and clinical reports suggest histotripsy stimulates an anti-tumor immune response in the adult population. We previously demonstrated that histotripsy ablation of NB xenograft tumors enhances tumor necrosis factor-alpha secretion, inducing apoptosis. We hypothesized that histotripsy induces both local and distal abscopal anti-tumor immune response in neuroblastoma, resulting in increased killing of tumor cells. Methods: Myc-expressing neuro-2a cells were subcutaneously and synchronously injected into each flank of immunocompetent A/J mice. Histotripsy was applied with a custom system to approximately 80% of one flank tumor when it reached 200 – 300 mm3. Six days later, single cell RNA sequencing (scRNAseq) libraries were prepared for histotripsy treated tumors, synchronous contralateral tumors, and tumors from untreated control mice. Sequencing files were processed with Cell Ranger and downstream analyses were done with Seurat, followed by Kruskal-Wallis test for cell proportions comparison. Flow cytometry was used to corroborate these findings using anti-CD8 (T cells) and CD11b (macrophages). Results: Tumors from untreated control mice were over two-fold larger than both histotripsy-treated tumors six days after treatment (p=0.03) as well as tumors contralateral to the histotripsy treated tumors (p<0.05), suggesting an abscopal effect. High-quality scRNAseq data were obtained from 3 untreated tumors and 2 each from histotripsy and contralateral tumors. The proportion of cytotoxic CD8+ T cells were significantly higher in histotripsy as well as contralateral tumors compared to untreated controls (p=0.029). Similarly, anti-tumor M1 macrophages had a non-significant trend higher (p=0.27) while pro-tumor M2 macrophages were significantly decreased (p=0.029) in controls compared to treated and contralateral tumors. These findings were validated with flow cytometry of both CD8 and CD11b markers (p<0.05, respectively). NB cells from treated and contralateral tumors had decreased Myc expression (p<0.001) in addition to suppression of cell cycle and growth-related pathways relative to control tumors, including Myc targets, G2M checkpoint, and E2F targets pathways (p<0.001, respectively). Treated and contralateral tumor cells also had activated expression pathways of inflammatory response, regulation of chemokines and cytokines, response to interferon, and antigen processing and presentation when compared to controls (p<0.001, respectively). Conclusions: Our findings show that histotripsy can generate an immune cell activation response in treated and distal tumors in NB models, reducing proliferation of the targeted tumor as well as having an abscopal effect. These findings suggest that histotripsy may sensitize NB tumors to T cell dependent targeted strategies such as PD-1 inhibition. Citation Format: Yuqing Xue, Natalia Antonides-Jensen, Fernando Flores-Guzman, Lydia L. Wu, Jacky Gomez-Villa, Muskan Singh, Kenneth B. Bader, Sonia L. Hernandez, Mark A. Applebaum. Histotripsy induces an anti-tumor immune response with an abscopal effect in a syngeneic neuroblastoma mouse model [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer— From Biology to Breakthrough Therapies; 2025 Sep 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_2): nr A029.
背景:尽管最近的治疗进展,高危神经母细胞瘤(NB)患者仍然需要改进的治疗方案。组织切片术是一种通过气泡激活进行非热组织消融的聚焦超声治疗。最近的临床前和临床报告表明,组织学检查可以刺激成年人的抗肿瘤免疫反应。我们之前证明了NB异种移植物肿瘤的组织切片消融可增强肿瘤坏死因子- α的分泌,诱导细胞凋亡。我们假设,组织切片法在神经母细胞瘤中诱导局部和远端体外抗肿瘤免疫反应,从而增加肿瘤细胞的杀伤。方法:将表达myc的神经2a细胞同步皮下注射到免疫活性A/J小鼠的两侧。当肿瘤面积达到200 - 300 mm3时,采用自定义系统对约80%的侧腹肿瘤进行组织切片。6天后,制备单细胞RNA测序(scRNAseq)文库,用于组织切片处理的肿瘤、同步对侧肿瘤和未处理的对照小鼠的肿瘤。测序文件用Cell Ranger处理,下游分析用Seurat完成,然后用Kruskal-Wallis测试进行细胞比例比较。流式细胞术用抗cd8 (T细胞)和CD11b(巨噬细胞)证实了这些发现。结果:治疗6天后,对照组小鼠的肿瘤比两组小鼠的肿瘤大2倍以上(p=0.03),比两组小鼠的肿瘤大2倍以上(p=0.03),比两组小鼠的肿瘤对侧大2倍以上(p<0.05),提示有体外作用。从3个未经治疗的肿瘤中获得高质量的scRNAseq数据,从组织学和对侧肿瘤中各获得2个数据。细胞毒性CD8+ T细胞在组织学和对侧肿瘤中的比例明显高于未治疗的对照组(p=0.029)。同样,与治疗组和对侧肿瘤相比,对照组中抗肿瘤M1巨噬细胞呈非显著性升高趋势(p=0.27),而促肿瘤M2巨噬细胞显著降低(p=0.029)。CD8和CD11b标记物的流式细胞术验证了这些发现(分别为p&;lt;0.05)。治疗肿瘤和对侧肿瘤的NB细胞Myc表达降低(p<0.001),并且相对于对照肿瘤抑制细胞周期和生长相关通路,包括Myc靶点、G2M检查点和E2F靶点通路(分别为p&;lt;0.001)。与对照组相比,治疗组和对侧肿瘤细胞的炎症反应、趋化因子和细胞因子的调节、对干扰素的反应、抗原加工和递呈的表达途径也被激活(p<0.001)。结论:我们的研究结果表明,在NB模型中,组织切片法可以在治疗肿瘤和远端肿瘤中产生免疫细胞激活反应,减少目标肿瘤的增殖,并具有体外作用。这些发现表明,组织切片可能使NB肿瘤对T细胞依赖的靶向策略(如PD-1抑制)敏感。引用格式:薛玉青,Natalia Antonides-Jensen, Fernando Flores-Guzman, Lydia L. Wu, Jacky Gomez-Villa, Muskan Singh, Kenneth B. Bader, Sonia L. Hernandez, Mark A. Applebaum。在同基因神经母细胞瘤小鼠模型中,组织切片法诱导具有体外效应的抗肿瘤免疫反应[摘要]。AACR癌症研究特别会议论文集:儿童癌症的发现和创新-从生物学到突破性疗法;2025年9月25日至28日;波士顿,MA。费城(PA): AACR;癌症研究2025;85(18_Suppl_2): nr A029。
期刊介绍:
Cancer Research, published by the American Association for Cancer Research (AACR), is a journal that focuses on impactful original studies, reviews, and opinion pieces relevant to the broad cancer research community. Manuscripts that present conceptual or technological advances leading to insights into cancer biology are particularly sought after. The journal also places emphasis on convergence science, which involves bridging multiple distinct areas of cancer research.
With primary subsections including Cancer Biology, Cancer Immunology, Cancer Metabolism and Molecular Mechanisms, Translational Cancer Biology, Cancer Landscapes, and Convergence Science, Cancer Research has a comprehensive scope. It is published twice a month and has one volume per year, with a print ISSN of 0008-5472 and an online ISSN of 1538-7445.
Cancer Research is abstracted and/or indexed in various databases and platforms, including BIOSIS Previews (R) Database, MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.